Literature DB >> 1942776

Urine glycosaminoglycans in congenital and acquired nephrotic syndrome.

L P Jadresic1, G Filler, T M Barratt.   

Abstract

To evaluate the specificity of a raised heparan sulphate (HS) excretion previously reported in four children with congenital nephrotic syndrome (CNS), we measured the urinary excretion of HS and chondroitin sulphate (CS) in seven children with Finnish-type congenital nephrotic syndrome (CNSF), seven with diffuse mesangial sclerosis (DMS), nine with focal segmental glomerulosclerosis (FSGS), 14 with steroid-sensitive nephrotic syndrome of whom eight had a biopsy confirming minimal change histology (SSNS), and 17 controls. The urine HS/CS ratio in normal children had a median of 0.36 (observed range 0.21 to 0.68) and was independent of age. HS/CS ratio was significantly greater than controls in CNSF (median 0.80, range 0.43 to 1.28), DMS (median 0.81, range 0.49 to 1.13) and FSGS children (median 0.66, range 0.38 to 1.6), but was not in SSNS (median 0.44, range 0.28 to 0.70). There was a positive correlation between the HS/CS ratio and urine albumin excretion. High HS/CS ratios are not diagnostic of a particular histological variety of CNS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1942776     DOI: 10.1038/ki.1991.211

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

1.  Glomerular anionic charge in congenital nephrotic syndrome of the Finnish type.

Authors:  P Ljungberg; J Rapola; C Holmberg; H Holthöfer; H Jalanko
Journal:  Histochem J       Date:  1995-07

2.  Glycosaminoglycans in urine and amniotic fluid in congenital nephrotic syndrome of the Finnish type.

Authors:  P Ljungberg
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

Review 3.  Management of congenital nephrotic syndrome of the Finnish type.

Authors:  C Holmberg; M Antikainen; K Rönnholm; M Ala Houhala; H Jalanko
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.